window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Therapeutic Areas

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Otsuka secures EU approval for Inaqovi combination therapy in acute myeloid leukaemia

    Inaqovi in combination with venetoclax has received an amended European [...]

    June 24, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Pheno Therapeutics gains FDA clearance for first-in-human multiple sclerosis drug PTD802

    Neurological pathway illustration showing myelin sheath repair; MRI brain imaging; [...]

    June 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ViiV Healthcare gains FDA Priority Review for paediatric Tivicay expansion to newborns

    ViiV Healthcare has secured FDA Priority Review for its application [...]

    June 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends NHS access to teplizumab for early type 1 diabetes

    The UK health watchdog NICE has recommended NHS reimbursement of [...]

    June 22, 2026
  • Advanced Therapies,Clinical & Regulatory,Genomics and sequencing,Therapeutic Areas

    Atsena advances gene therapy ATSN-201 into Phase 3 trial for inherited blindness

    Atsena Therapeutics has dosed the first patient in the Phase [...]

    June 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Pierre Fabre wins EU approval for first-line BRAFTOVI regimen in BRAF-mutant colorectal cancer

    The European Commission has approved BRAFTOVI in combination with cetuximab [...]

    June 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    African health leaders launch Imara framework to strengthen sickle cell disease care across Africa

    African health leaders have launched the Imara Sickle Cell Framework [...]

    June 19, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Genomics and sequencing,Pharmaceuticals and therapeutics,Therapeutic Areas

    Scribe Therapeutics secures $25M CIRM backing to advance CRISPR cardiometabolic therapies

    Scribe Therapeutics has secured more than $25 million in CIRM [...]

    June 18, 2026
  • Advanced Therapies,Drug Discovery & Development,Therapeutic Areas

    Resolution Therapeutics expands regenerative macrophage pipeline with in vivo mRNA programme

    Resolution Therapeutics has expanded its regenerative macrophage therapy pipeline with [...]

    June 18, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Gesynta reaches halfway point in Phase 2 endometriosis trial

    Gesynta Pharma has randomised half of the planned patients in [...]

    June 18, 2026
Previous111213Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Agenus reports deep responses with immunotherapy in Phase 2 colon cancer study
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • CEPI funds Minapharm’s Phase 1 Bundibugyo Ebola vaccine programme
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development
  • Sagimet prepares Phase 3 acne trial for first US patients
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top